ANRO

Alto Neuroscience

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 2

Sell signal 0

consensus rating "Strong Buy"

EPS Beats Expectation

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About ANRO

Alto Neuroscience, Inc.

A clinical-stage biopharmaceutical company in California

Industry

Pharmaceutical

Established Date

03/25/2019

Listing Date

02/02/2024

Exchange

New York Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.altoneuroscience.com

Security Type

Common stock

Office address

369 South San Antonio Road, Los Altos, CA 94022

Business

Introduction

Alto Neuroscience, Inc., was incorporated in Delaware on March 25, 2019. The company is headquartered in Los Altos, California. The company is a clinical-stage biopharmaceutical company whose mission is to redefine psychiatry by leveraging neurobiology to develop personalized and efficient treatment options. Building on more than a decade of research by its founder, Dr. Amit Etkin, the company's goal is to gain insight into brain function and more effectively match patients with the right drugs by using treatments that target specific patient groups. The company's current product line includes five clinical-stage assets, initially targeting major depression (MDD) and schizophrenia populations with independent brain-based biomarkers. Each of the company's clinical-stage product candidates has been evaluated through at least initial phase 1 clinical trials and has been observed to be well tolerated. The company's most advanced programs, including two product candidates evaluated in ongoing late-stage (2b or later) trials, are supported by prospective repeating evidence of clinical activity in the biomarker signature population.

Company Financials

EPS

ANRO has released its 2024 Q4 earnings. EPS was reported at -0.56, versus the expected -0.66, beating expectations. The chart below visualizes how ANRO has performed over recent quarters, highlighting trends in earnings surprises.